Hong Kong Construction Stock News

Recent Performance Snapshot for Tencent Holdings stock Tencent Holdings (SEHK:700) has drawn investor attention after a period where the stock declined 4.2% over the past day, 7.3% over the past week and about 6% over the past month. Over the past 3 months, Tencent Holdings is down about 17.9%, with the year to date return showing a decline of 33.4%. On a 1 year basis, the total return is down 17.6%, while the 3 year total return stands at 25.1% and the 5 year total return reflects a decline...

Market forces rained on the parade of China Tobacco International (HK) Company Limited ( HKG:6055 ) shareholders today...

Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Tristate...

Growth has become harder to find as major economies send mixed signals, from weak European PMIs and contracting UK services to patchy strength across Asia and Latin America. In this kind of stop start backdrop, many investors are looking for companies where management is clearly aligned with shareholders and analysts see room for further expansion. The Fast Growing Stocks With High Insider Ownership screener focuses on exactly that combination. It highlights businesses where insiders have...

JBM (Healthcare) (SEHK:2161) has posted its FY 2026 first half results with revenue of HK$429.6 million and basic EPS of HK$0.141, setting the stage for how investors assess the latest move in profitability. The company has reported revenue of HK$398.9 million in FY 2025 H1, HK$383.3 million in FY 2025 H2, and HK$429.6 million in FY 2026 H1, while basic EPS was HK$0.116 in FY 2025 H1, HK$0.108 in FY 2025 H2, and HK$0.141 in the latest half. These figures sit against a slightly softer net...

Why the SSE 180 Index Addition Matters for COSCO SHIPPING Energy Transportation COSCO SHIPPING Energy Transportation (SEHK:1138) was recently added to the SSE 180 Index, a move that can draw more attention from institutional investors and index-tracking funds. This index inclusion often leads to higher visibility in the domestic market, which can influence trading volumes and liquidity. For existing and potential shareholders, the change raises questions about how the stock’s fundamentals...

Amidst a backdrop of shifting monetary policies and mixed economic signals in Asia, investors are closely watching regional markets for opportunities. Penny stocks, often associated with smaller or emerging companies, continue to capture interest due to their potential for substantial growth when supported by strong financials. While the term "penny stock" may seem outdated, the investment potential remains significant as these companies can offer unique value propositions that larger firms...

As the Asian markets navigate a complex landscape marked by geopolitical developments and monetary policy shifts, investors are on the lookout for opportunities that align with current economic conditions. Penny stocks, though often seen as relics of speculative trading, still offer potential when backed by strong financials and growth prospects. This article explores three penny stocks in Asia that stand out for their robust fundamentals, offering a unique opportunity for investors seeking...

China Medical System Holdings announced that its New Drug Application for Silevimig Injection, a fully human bispecific antibody for passive immunization after rabies exposure, was approved by China’s National Medical Products Administration on 22 June 2026, and the company obtained the drug registration certificate. This approval introduces the world’s first dual-epitope rabies bispecific antibody, adding an eighth commercialized innovative drug to the group’s portfolio and enhancing its...

In June 2026, InnoCare Pharma reported that over 40 clinical studies of its BTK inhibitor orelabrutinib were presented at the European Hematology Association Congress, highlighting consistent efficacy and safety across multiple blood cancers and patient populations in the United States, Europe, and China. Beyond confirming strong responses in chronic lymphocytic leukemia and marginal zone lymphoma, the data suggested orelabrutinib may offer a differentiated safety profile and meaningful...

As Asian markets navigate a complex landscape of economic shifts and policy changes, investors are increasingly exploring diverse opportunities within the region. Penny stocks, despite their somewhat outdated label, remain an intriguing investment area for those seeking potential growth in smaller or newer companies. This article will explore three such stocks that stand out due to their financial strength and potential for long-term success amidst current market conditions.

As Asia's financial landscape continues to evolve, investors are paying close attention to the region's dynamic markets, where recent developments such as Japan's interest rate hikes and China's mixed economic indicators have created a complex backdrop for investment. Amidst these changes, identifying stocks with strong fundamentals and growth potential can be crucial for navigating the current environment.

Auntea Jenny (Shanghai) Industrial Co., Ltd. ( HKG:2589 ) stock is about to trade ex-dividend in 3 days. The...

Last week, Kelfred Holdings Limited ( HKG:1134 ) insiders, who had purchased shares in the previous 12 months were...

China Frontier Technology Group's (HKG:1661) stock price has dropped 16% in the previous week, but insiders who sold...

Readers hoping to buy Min Xin Holdings Limited ( HKG:222 ) for its dividend will need to make their move shortly, as...

The Cross-Harbour (Holdings) Limited ( HKG:32 ) stock is about to trade ex-dividend in 3 days. The ex-dividend date is...

Phancy Group (SEHK:6682) is back in focus after Frost & Sullivan’s 2026 AI Infrastructure Orchestration Platform White Paper named its Rise vGPU a Tier 1 Leading Platform and ranked ModelHub highest in model management. See our latest analysis for Phancy Group. Despite the Frost & Sullivan recognition, Phancy Group’s recent momentum has been weak, with the share price at HK$27.94 and the 1-year total shareholder return declining 42.33%. This reflects pressure after a year of falling share...

Rising oil and gasoline prices are back in focus, with Canadian inflation for May expected around 3% and the Bank of Canada watching closely for any spillover into core prices. At the same time, oil markets are reacting to headlines about a U.S. and Iran memorandum of understanding to end the Middle East war and reopen the Strait of Hormuz. For energy sector stocks, that mix of higher fuel costs and cooling crude prices can reshape profit outlooks and risk. This article explains how those...

Simcere Pharmaceutical Group (SEHK:2096) has drawn fresh attention after agreeing to fund an exploratory idiopathic pulmonary fibrosis project with Stanford Medicine, securing an option to in-license a first in class molecule with full global rights. See our latest analysis for Simcere Pharmaceutical Group. The Stanford IPF collaboration comes at a time when Simcere Pharmaceutical Group’s shares are trading at HK$9.58, with a 30 day share price return down 9.62% and a year to date share price...

Why InnoCare Pharma Stock Is In Focus After EHA 2026 InnoCare Pharma (SEHK:9969) has drawn fresh attention after presenting data from more than 40 clinical studies of its BTK inhibitor orelabrutinib at the European Hematology Association 2026 Congress. The company highlighted outcomes across several hematological cancers, including chronic lymphocytic leukemia, small lymphocytic lymphoma, marginal zone lymphoma, mantle cell lymphoma, diffuse large B cell lymphoma, and primary central nervous...

Shareholders might have noticed that HKR International Limited ( HKG:480 ) filed its full-year result this time last...

Precision Tsugami (China) (SEHK:1651) is back in focus after coverage highlighting its wide discount to estimated fair value, as the board prepares to approve annual results and consider a potential final dividend. See our latest analysis for Precision Tsugami (China). The recent focus on valuation comes after a powerful run in Precision Tsugami (China)'s stock, with a 93.8% 90 day share price return and a very large 3 year total shareholder return that points to strong long term compounding...

Earlier in June 2026, RemeGen announced that China’s National Medical Products Administration granted full approval for telitacicept in Sjögren’s disease and conditional approval in IgA nephropathy, both supported by positive Phase 2 and Phase 3 clinical data. These decisions expand telitacicept to five approved autoimmune indications in China, underscoring the clinical breadth of RemeGen’s first-in-class BLyS/APRIL dual-target biologic. We’ll now examine how this broadened telitacicept...